Clinical Edge Journal Scan

Even moderate exercise improves survival in breast cancer survivors


 

Key clinical point: Breast cancer (BC) survivors who were active or moderately active had an ~60% lower risk for mortality compared with those who were insufficiently active.

Major finding: Compared with insufficiently active participants, the risk for mortality was ~60% lower in active (hazard ratio [HR] 0.42; 95% CI 0.21-0.85) and moderately active (HR 0.40; 95% CI 0.17-0.95) participants.

Study details : Findings are from a cohort study including 315 postmenopausal BC survivors who were followed for a minimum of 2 years post-diagnosis.

Disclosures: This study was supported by the US National Cancer Institute. The authors declared no conflicts of interest.

Source: Chen LH et al. Association of physical activity with risk of mortality among breast cancer survivors. JAMA Netw Open. 2022;5(11):e2242660 (Nov 17). Doi: 10.1001/jamanetworkopen.2022.42660

Recommended Reading

Axillary radiotherapy: A good treatment option for sentinel node-positive cT1-2 breast cancer
Breast Cancer ICYMI
Axillary radiotherapy: A good treatment option for sentinel node-positive cT1-2 breast cancer
Breast Cancer ICYMI
Acupuncture relieves AI-related joint pain for up to a year in BC patients
Breast Cancer ICYMI
Triple-positive BC: Neoadjuvant pyrotinib+letrozole+dalpiciclib shows promise in phase 2
Breast Cancer ICYMI
Selective internal radiation therapy effective and safe in patients with BC and hepatic metastasis
Breast Cancer ICYMI
Prognostic impact of receptor conversion between primary breast cancer and bone metastases
Breast Cancer ICYMI
Prognostic impact of receptor conversion between primary breast cancer and bone metastases
Breast Cancer ICYMI
Obesity and advanced stage at diagnosis worsen recurrence rate in BC patients
Breast Cancer ICYMI
HR+/HER2− metastatic BC: Everolimus dose escalation+exemestane reduces grade ≥2 stomatitis
Breast Cancer ICYMI
HER2+ metastatic BC: Better survival outcomes with trastuzumab deruxtecan vs trastuzumab emtansine
Breast Cancer ICYMI